PHASE-II ASSESSMENT OF RECOMBINANT LEUKOCYTE-A INTERFERON WITH DIFLUOROMETHYLORNITHINE IN DISSEMINATED MALIGNANT-MELANOMA

被引：10

作者：

CREAGAN, ET ^{[1
]}

LONG, HJ ^{[1
]}

AHMANN, DL ^{[1
]}

SCHAID, DJ ^{[1
]}

机构：

[1] MAYO CLIN & MAYO FDN,CANC CTR STAT,ROCHESTER,MN 55905

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1990年 / 13卷 / 03期

关键词：

D O I：

10.1097/00000421-199006000-00008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sixteen patients with advanced melanoma received IFN-α2A, 36 x 106 U/m2 i.m., on days 3-7 with 2.25 g/m2 DFMO p.o. on days 1-7. We observed no objective regressions. Median time to progression was 1.2 months with a median survival of 5.2 months. A flu-type syndrome was the predominant sequela. From the dose and schedule that we utilized, this regimen holds little promise against disseminated malignant melanoma.

引用

页码：218 / 220

页数：3